Showing 4761-4770 of 6036 results for "".
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- Edenlux Launches Campaign for Otus Personal EYE-Trainerhttps://modernod.com/news/edenlux-launches-campaign-for-otus-personal-eye-trainer/2480458/The Otus personal eye-trainer, which was created by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the
- jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapyhttps://modernod.com/news/jcyte-identifies-key-anatomical-biomarker-predictive-of-substantial-restoration-of-visual-function-in-retinitis-pigmentosa-patients-treated-with-jcell-therapy/2480452/jCyte announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its phase 2b study, the largest randomized clinical trial ever con
- Kala Pharmaceuticals Acquires Combangio, Maker of Regenerative Biotherapies for Severe Ocular Surface Diseaseshttps://modernod.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/Kala Pharmaceuticals announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex w
- Hydrus Microstent Lowers Visual Field Loss by 47%, According to New 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/Ivantis, developer of the Hydrus Microstent, announced new data from its 5-year HORIZON t
- Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for Zepto Cataract Surgical Platformhttps://modernod.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/Centricity Vision announced that Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the Zepto Platform. "We're confident that Zepto will have a huge impact on the cataract surgery market," Mr. Pinkney said.
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- LumiThera Acquires Diopsys, Provider of Light-Based Theranostic Approach to Treat Ocular Diseasehttps://modernod.com/news/lumithera-acquires-diopsys-provider-of-light-based-theranostic-approach-to-treat-ocular-disease/2480430/LumiThera announced its entry into a definitive merger agreement with Diopsys, a provider of modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Under the terms of
- Ziemer USA Announces Partnership With CorneaGenhttps://modernod.com/news/ziemer-usa-announces-partnership-with-corneagen/2480429/Ziemer USA, a wholly owned subsidiary of Switzerland-based Ziemer AG, announced a new partnership with CorneaGen. "We have started an exciting new collaboration with CorneaGen," said David Bragg, President of Ziemer USA & Canada. "Through combined developme